The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of the vascular-disrupting agent BNC105P in combination with gemcitabine-carboplatin in platinum-sensitive ovarian cancer patients in first or second relapse.
Danny Rischin
Consultant or Advisory Role - Bionomics (U)
Research Funding - Bionomics
Philip James Beale
No relevant relationships to disclose
Emma Caroline Rossi
No relevant relationships to disclose
Jeffrey C. Goh
No relevant relationships to disclose
Michelle Margaret Vaughan
No relevant relationships to disclose
Meaghan Elizabeth Tenney
No relevant relationships to disclose
Julie Martyn
No relevant relationships to disclose
Dirkje Willemien Sommeijer
No relevant relationships to disclose
Jose Luis Iglesias
Employment or Leadership Position - Bionomics
Gabriel Kremmidiotis
Employment or Leadership Position - Bionomics
Stock Ownership - Bionomics
Jeremy Andrew Simpson
Employment or Leadership Position - Bionomics
Elizabeth E. Doolin
Employment or Leadership Position - Bionomics
Stock Ownership - Bionomics
Tina C. Lavranos
Employment or Leadership Position - Bionomics
Stock Ownership - Bionomics
Annabell F. Leske
Employment or Leadership Position - Bionomics
Stock Ownership - Bionomics
Anne-Sophie Veillard
No relevant relationships to disclose
Martin R. Stockler
No relevant relationships to disclose